Bardoxolone (CDDO, RTA 401)

Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are...

More>>

Bardoxolone methyl

Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). T...

More>>

TG 101348

TG101348 (SAR302503) is an orally available inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseas...

More>>

TG 101209

TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively. ...

More>>

CYT 387 (CYT11387)

CYT 387 is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 and 18 nM respectively. CYT387 competes w...

More>>

LY 2784544

LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor with an IC50 of 68 nM. The antiproliferative activity of LY2784544 and its abilit...

More>>

Ruxolitinib (INCB018424)

Ruxolitinib (INCB018424) is an orally bioavailable JAK inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib (INCB 0184...

More>>

Tofacitinib (CP-690550)

Tofacitinib (Tasocitinib, CP-690550) is a novel, small molecule inhibitor of JAK3 with an IC50 with 1 nM, and exhibits rather indiscriminate activity ...

More>>

AZD 1480

AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with an IC50 of 0.26 nM. JAK2 inhibitor AZD1480 inhibits JAK2 activati...

More>>

NSC 74859 (S3I-201)

NSC 74859 (S3I-210) is a cell-permeable amidosalicylic acid compound that binds Stat3-SH2 domain and prevents Stat3 phosphorylation/activation, dimeri...

More>>

Total: 26 Page: 2 / 2 First ←Previous Next→ End